Shafi Ullah Khan is a highly accomplished interdisciplinary medicinal chemist with a Ph.D. from Monash University and extensive experience across the drug discovery pipeline. His expertise includes Computer-Aided Drug Design (CADD), synthetic chemistry, and biological evaluation. Currently, as a Marie Curie Post-doctoral Fellow at INSERM in France, he is leading a project to develop UBE2N inhibitors to sensitize ovarian cancers to PARP inhibitors. With an impressive publication record of 69 refereed journal articles, Dr. Khan has a proven track record of integrating computational and experimental methods. He has also served as an Associate Professor, teaching and supervising doctoral students. His career objective is to bridges in silico predictions with pre-clinically relevant experimental validation to accelerate the development of patient-centric cancer therapies.